Page 3


  • A micrograph of a myeloma neoplasm in a bone marrow biopsy.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Bristol Myers says next-gen blood cancer drug hits goal in key study

    The drug, iberdomide, is one of a few protein-degrading medicines the company hopes to become successors to its blockbuster Revlimid franchise.

  • A Pfizer logo sits atop the entrance of the company's Ian C. Read Laboratories in Cambridge, Massachusetts, on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip
    Obesity drugs

    Pfizer buys back into obesity drug chase with $4.9B Metsera deal

    The deal ends a short run as a publicly traded company for Metsera, which is being sold for more than double its IPO price amid enthusiasm for its weight loss medicines.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    FDA clears under-the-skin Keytruda; MBX shares double on study data

    The clearance of Keytruda QLEX follows similar approvals for Bristol Myers and Roche. Elsewhere, MBX’s parathyroidism drug impressed investors and Roche claimed success in a breast cancer study.

  • A human brain is imaged with a MRI scan.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    IPO window

    MapLight lines up an IPO in bid to challenge Bristol Myers schizophrenia drug

    The company, which is developing a competitor to Cobenfy, aims to become one of rare biotechs to price a large IPO of late.

  • FDA sign
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    FDA clears first Barth syndrome drug amid scrutiny of rare disease stance

    After an earlier rejection that drew criticism from some observers, the FDA quickly accepted Stealth BioTherapeutics’ new application and cleared its drug’s use.

    FDA
  • A person in business attire points while seated at a conference table with other people.
    Image attribution tooltip
    Elijah Nouvelage via Getty Images
    Image attribution tooltip
    Vaccines

    CDC panel, recast by RFK Jr., softens COVID vaccine recommendations

    After a tumultuous two-day meeting marked by confusion and missteps, an advisory committee endorsed guidelines that would urge people to discuss vaccination's benefits and risks with their physician.

  • An illustration of human liver anatomy against a stylized background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Roche dives into MASH with $2.4B deal for 89bio

    Roche’s CEO claimed 89bio’s drug, which is in late-stage testing, has the potential to show “best-in-disease efficacy” for many people with the condition.

  • Bob Langer, Corey McMann, Kwesi Frimpong-Boateng and Michael Langer stand for a portrait in front of a wall of rocks.
    Image attribution tooltip
    Permission granted by T.Rx Capital
    Image attribution tooltip
    Emerging biotech

    A new biotech venture firm emerges, led by Bob Langer’s son

    T.Rx Capital was co-founded by Michael Langer, former Pear Therapeutics CEO Corey McCann and Eli Lilly veteran Kwesi Frimpong-Boateng, and raised just shy of $80 million for its first fund.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Arvinas reboots, cuts more staff; Porges joins Lazard

    Pfizer and Arvinas plan to out-license their partnered drug vepdegestrant. Elsewhere, Novo shared more data for oral Wegovy and Vertex reached a deal in Italy for coverage of its gene editing medicine Casgevy. 

  • People in business attire site around tables in a conference room.
    Image attribution tooltip
    Elijah Nouvelage / Stringer via Getty Images
    Image attribution tooltip
    Vaccines

    CDC panel recommends splitting measles, varicella shots

    The committee reconvened Friday to re-do a vote on coverage of the combined MMRV shot through the Vaccines for Children program, citing panelists’ confusion the day before. 

    Updated Sept. 19, 2025
  • A sign with Biogen's logo sits outside the company's Cambridge, Massachusetts, headquarters on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip

    Biogen to buy startup Alcyone, eyeing easier delivery of RNA drugs

    The purchase gives Biogen full access to an implantable device that could help patients avoid the repeat lumbar punctures required for drugs like Spinraza.

  • People in business attire speak while seated at a conference table.
    Image attribution tooltip
    Elijah Nouvelage via Getty Images
    Image attribution tooltip
    Vaccines

    CDC advisers postpone vote to delay some newborns’ hepatitis B shot

    Members of ACIP voted to table a planned vote on withholding some infants’ first hepatitis B vaccine dose, adding more confusion to an already muddied meeting.

  • A person in business attire speaks into a microphone while seated at a desk.
    Image attribution tooltip
    Kevin Dietsch via Getty Images
    Image attribution tooltip
    Vaccines

    Fired CDC director says RFK Jr. aims to change childhood vaccine schedule

    Susan Monarez told Senators at a hearing Wednesday that Robert F. Kennedy Jr. pushed her out for refusing to rubber-stamp changes.

  • A sign with the letters GSK hangs on the side of an office building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Pharma reshoring

    GSK ups US investment with $30B spending plan

    The British drugmaker’s commitment comes as some of its pharma peers question their U.K. presence amid a widening row there over pricing polices.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Lilly, Novo showcase new obesity drug data; Fasenra falls short in COPD

    Lilly claimed success in a head-to-head trial of oral GLP-1 drugs. Elsewhere, Novo planned a new weight loss trial and an AI-focused startup raised its second “megaround.”

  • Close-up on a scientist using a mobile app on a digital tablet while working at the laboratory
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Roivant pill succeeds in rare inflammatory disease trial

    A drug licensed from Pfizer will be submitted to the FDA next year after study results showed it reduced dermatomyositis symptoms and steroid use.

  • An older women's eye is seen up close.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Startup launches

    Ollin debuts with $100M and plans to challenge top-selling eye drugs

    Backed by a trio of top venture firms, Ollin is working on a pair of medicines it believes can one-up Roche’s Vabysmo and Amgen’s Tepezza.

  • An illustration of red blood cells.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    CSL nabs option to acquire a startup and its blood-clotting drug

    A deal with Dutch startup VarmX gives CSL an option to buy a Phase 3-ready drug that could reverse the effects of popular anticoagulants like Eliquis, which carry the risk of internal bleeding.

  • A 3D illustration of human lungs.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Startup launches

    Former CinCor execs reunite to helm new biotech startup

    Led by former founders of a biotech AstraZeneca acquired in 2023, AllRock Bio is starting out with a drug licensed from Sanofi that’ll be tested against pulmonary arterial hypertension.

  • People in business attire sit around a conference table.
    Image attribution tooltip
    Elijah Nouvelage / Stringer via Getty Images
    Image attribution tooltip
    Vaccines

    A key CDC panel meets today to discuss vaccines. Here’s what to know.

    The remade ACIP panel is set to vote today on recommendations for use of vaccines for measles and hepatitis B. They’ll meet again tomorrow to discuss COVID shots.

    Updated Sept. 15, 2025
  • A sign spelling Novartis hangs on the side of a building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Novartis dives deeper into protein degraders with second Monte Rosa deal

    The company’s new partnership with the "molecular glue” drug developer is broad, focused on immunology and could be worth up to $5.7 billion.

  • A person wearing a shirt that says "Mosaic" stands and speaks in front of two computer screens showing text and images.
    Image attribution tooltip
    Permission granted by Radiology Partners
    Image attribution tooltip

    Foundation models are medtech’s newest trend. But what are they?

    The AI models, which are built on massive datasets and can be adapted to multiple tasks, have become a part of medtech companies’ lexicon in the past few years.

  • An illustration of human lungs with a geometrical effect.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    ATyr shares plunge on trial miss in inflammatory lung disease

    The company’s market value was largely wiped out after a therapy it’s been developing for pulmonary sarcoidosis missed its main study goal.

  • A large group of dosing pens for subcutaneous injection of anti-obesity medication piled in a heap.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Ozempic for cancer? Signs point to potential benefits of GLP-1s in oncology

    Early academic research suggests various ways weight loss drugs could have an impact in cancer care.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Takeda poaches top Lilly exec; Maze soars on early PKU drug data

    Rhonda Pacheco, who oversaw Zepbound’s launch, will run Takeda’s U.S. business. Elsewhere, early data suggested Maze might have a “best-in-class” rare disease drug and Arrowhead challenged Ionis in court.